Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
4‑part, open‑label, multicenter, multinational study of venglustat in Gaucher disease
2014-002550-39Phase 2Active
- Sponsor
- Sanofi
- Start
- Apr 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of venglustat in Gaucher disease (GD) and Gaucher disease type 3, sponsored by Sanofi. Primary endpoint: Number of patients with adverse events. Started Apr 2016; status: active.
02
Drugs
venglustat
03
Conditions
Gaucher disease (GD)Gaucher disease type 3
Beyond the preview
Go deeper on 2014-002550-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-002550-39.